Аналитики повысили рейтинг акций Apotex Health Corp. до «покупать» после рекортного IPO

AnalystsPronably all underwriters but coffeeless , so not bothering to check. Seeing it as “well-stocked, well-positioned,” Desjardins Securities analyst Gary Ho initiated coverage of Apotex Health Corp. with a “buy” rating on Monday, calling it “Canada’s generic champion.” On June 10, the country’s largest drug company raised $1.3-billion in its market debut by selling shares at $24 each, the top end of the range set by investment bankers underwriting the largest Canadian initial public offering since Definity Financial Corp., an insurer, went public in a $1.4-billion share offering in 2021. On Monday, several analysts on the Street launched coverage of Toronto-based Apotex after coming off research restrictions related to the IPO. “We are positive on APTX for several reasons: (1) Apotex holds 23 per cent of the Canadian generic market—one in five generic prescriptions in Canada is an Apotex product —a dominant position supported by 50+ years of brand equity, deep pharmacy relationships and a manufacturing footprint that competitors cannot easily replicate. (2) Demand is driven by an aging population and healthcare system cost pressures rather than the economic cycle, providing resilience across macro environments. (3) The business is diversifying rapidly—Conventional Generics fell to 46 per cent of revenue in FY26 from 59 per cent in FY23 (ex VLLP), with Specialty Generics and Brands & Biosimilars capturing share, tilting the portfolio toward higher-margin, higher-barrier products. (4) A forward pipeline of 480+ products (70 per cent first-to-market) across Canada, the US and International provides a visible organic growth runway. (5) Apo-Semaglutide, approved in May 2026 as one of Canada’s first generic semaglutides, represents a near-term catalyst, targeting a combined Ozempic/Wegovy market of $2.8-billiob in Canada in 2025,“ Mr. Ho said. In a client report released before the bell, he said he conducted proprietary channel checks with industry contacts at a top three Canadian generic manufacturer and a top five global branded pharmaceutical company. “Our key takeaways are: (1) first-to-market is the single largest driver of value in generics, with sticky share given the operational friction of switching suppliers and EBITDA margins on first-to-market products that can be more than 2-times consolidated margins; (2) branded margins during patent protection are highly attractive once R&D is recovered—not every LOE is an easy generic opportunity; (3) the Canadian market is attractive and cash-generative, with the TPF providing pricing stability, although better growth increasingly lies in complex generics, injectables and biosimilars; and (4) scale and portfolio breadth matter, as larger manufacturers with single-source molecules can blend down rebate rates across the basket—a structural advantage for Apotexm," he said. Mr. Ho said he sees Apotex’s risk profile as “manageable, with most items inherent to the industry vs being company-specific.” “First, regulatory risk—first-to-market positioning depends on Health Canada and FDA approval timing, and competitors with similar pipelines can leapfrog key launches,“ he explained. ”Second, pricing pressure—Canadian generic pricing is governed by the pCPA’s TPF (extended in June 2026 through October 2028), and national pharmacare could affect pricing dynamics over time. Third, manufacturing facility risk—the Richmond Hill site, which produces sterile ophthalmics for the U.S. market, received an FDA Warning Letter and an Official Action Indicated classification in 2025, prompting Apotex to voluntarily discontinue certain U.S. production while remediating." Mr. Ho set a target of $40 per share, falling 67 cents under the average on the Street. Others initiated coverage on Monday include: * RBC’s Douglas Miehm with an “outperform” rating and $43 target. “We initiate on Apotex with an Outperform and $43 PT, seeing APTX as a highly differentiated generics firm that should underpin a premium valuation. As leader in the attractive CDN generic industry (23-per-cent share) and a top-10 player in the U.S. market, we believe APTX can successfully harness improving industry fundamentals, capturing a disproportionate amount of economic value due to its strong first to market (FTM) abilities, and allow it to maintain industry high ROIC and strong financial metrics vs comps,” said Mr. Miehm. * BMO’s Evan Seigerman with an “outperform” rating and $39 target.